Alzheimers Disease and other Cognitive Disorders
Resources
Basic Information
Introduction & Causes of Cognitive DisordersDementiaAlzheimer's DiseaseOther Cognitive DisordersDementia Coping Skills & Behavior ManagementTraumatic Brain Injury (TBI)Conclusion and Resources
More InformationLatest News
Brain's Iron Stores May Be Key to Alzheimer'sHormones May Explain Greater Prevalence of Alzheimer's in WomenMiddle-Age Obesity Linked to Higher Odds for DementiaCould Crohn's, Colitis Raise Dementia Risk?5 Healthy Steps to Lower Your Odds for Alzheimer'sCOVID-19 Brings New Challenges to Alzheimer's CaregivingAlzheimer's Gene Linked to Severe COVID-19 RiskHealthier Heart, Better Brain in Old AgeAHA News: Hearing Loss and the Connection to Alzheimer's Disease, DementiaBrain Plaques Signal Alzheimer's Even Before Other Symptoms Emerge: StudyCertain Gene Might Help Shield At-Risk People From Alzheimer'sHow to Connect With Nursing Home Patients in QuarantineHow to Ease Loved Ones With Alzheimer's Through the PandemicCaring for Dementia Patient During Pandemic? Try These Stress-Busting TipsRecovery From Mild Brain Trauma Takes Longer Than Expected: StudyDaily Aspirin Won't Stop Dementia, Study FindsStudy Ties Brain Inflammation to Several Types of DementiaHeart Drug Combos Might Also Lower Your Dementia Risk: StudyU.S. Primary Care Docs Unprepared for Surge in Alzheimer's CasesMaria Shriver Sounds the Alarm on Women and Alzheimer'sTraumatic Brain Injuries Raise Risk of Psychiatric Ills in SoldiersGrowing Up in U.S. 'Stroke Belt' Bad for the Brain Later in LifeTwo Experimental Drugs Disappoint With Inherited Alzheimer'sGene Variant Ups Dementia Risk in Parkinson's Patients: StudyGene Variation May Protect Against Alzheimer's: StudyWhen Dementia Harms Speech, Native Language MattersEven 1 Night's Bad Sleep Can Raise Levels of a Brain 'Marker' for Alzheimer'sAHA News: Worried About Dementia? Check This Blood Pressure NumberStudy Might Point Alzheimer's Research in Whole New DirectionMore Doubt That Plaques in the Brain Cause Alzheimer'sObesity in Middle Age Could Raise Odds for Alzheimer's LaterCan Air Pollution Take a Toll on Your Memory?Animal Study Offers Hope for Treating Traumatic Brain InjuriesAlmost Half of Older Americans Fear Dementia, Try Untested Ways to Fight ItPeople Who Can't Read Face 2-3 Times Higher Dementia RiskEducation a Buffer Against Alzheimer's Among Blacks: StudyDown Syndrome Carries Raised Risk of Dementia by 55A Gene Kept One Woman From Developing Alzheimer's -- Could It Help Others?Number of Americans With Dementia Will Double by 2040: ReportIs Head Injury Causing Dementia? MRI Might ShowFamily Can Help Keep Delirium at Bay After SurgeryPro Soccer Players More Likely to Develop Dementia: StudyDrug Limits Damage of Brain InjuryYour Personality as a Teen May Predict Your Risk of DementiaWhat Helps Calm Agitated Dementia Patients?AHA News: Growing – and Aging – Hispanic Population at Risk for DementiaAHA News: Yo-Yoing Blood Pressure Could Be Bad for Those With Alzheimer'sGive Seniors a Memory Check at Annual Checkups, Experts SayFor People at High Risk, Evidence That Exercise Might Slow Alzheimer'sDementia Caregivers Often Face Sleepless Nights
Questions and AnswersVideosLinksBook Reviews
Related Topics

Aging & Geriatrics
Memory Problems
Elder Care

Two Experimental Drugs Disappoint With Inherited Alzheimer's

HealthDay News
by -- Robert Preidt
Updated: Feb 10th 2020

new article illustration

MONDAY, Feb. 10, 2020 (HealthDay News) -- Two experimental drugs do not appear to slow memory loss or mental decline in patients in the early stages of a rare, inherited form of Alzheimer's disease, according to initial results from a clinical trial.

The international phase 2 and 3 clinical trial separately evaluated the two drugs -- solanezumab (Eli Lilly and Co.), and gantenerumab (Roche and its U.S. affiliate, Genentech) -- in nearly 200 people with dominantly inherited Alzheimer's disease, also called autosomal dominant Alzheimer's disease.

People with this form of Alzheimer's suffer declines in memory and thinking skills starting in their 50s, 40s or even 30s.

The patients were followed for up to seven years, with an average of five years. Initial analysis suggests that neither drug achieved the primary outcome of the study, which was a slowing of mental decline as measured by thinking and memory tests.

"Although the drugs we evaluated were not successful, the trial will move us forward in understanding Alzheimer's," study director Dr. Randall Bateman, a professor of neurology at Washington University in St. Louis, said in a university news release.

The study can help guide future research into the disease, including the more common form that typically strikes after age 65, according to Bateman.

Alzheimer's-related brain changes that occur as the disease progresses are much the same in patients with the inherited, younger-onset and the late-onset forms of the disease, he explained.

Both forms have "silent" phases that begin up to two decades before symptoms appear. The disease process starts with the accumulation of plaques of the protein amyloid beta in the brain. The two drugs in the study were designed to target the protein.

A more detailed analysis of the trial's data will be presented for the first time April 2-5 at the Advances in Alzheimer's and Parkinson's Therapies annual meeting, in Vienna, Austria. Research presented at meetings is considered preliminary until published in a peer-reviewed journal.

More information

The Alzheimer's Association has more on younger-onset Alzheimer's disease.




Facebook

Amazon Smile

 

Children and Adult services are available now with no wait time.  

Please contact HBH at 860-548-0101, option 2.

 


powered by centersite dot net